| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ashish Dhir, S K Kulkarn. Risperidone, an atypical antipsychotic enhances the antidepressant-like effect of venlafaxine or fluoxetine: possible involvement of alpha-2 adrenergic receptors. Neuroscience letters. vol 445. issue 1. 2009-04-14. PMID:18778754. |
clinical studies have reported the beneficial outcome of addition of lower doses of risperidone to antidepressant therapy specifically with selective serotonin reuptake inhibitors (ssris) in the treatment of major depression. |
2009-04-14 |
2023-08-12 |
mouse |
| Francis E Lotrich, Robert E Ferrell, Mordechai Rabinovitz, Bruce G Polloc. Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. Biological psychiatry. vol 65. issue 4. 2009-04-10. PMID:18801474. |
risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. |
2009-04-10 |
2023-08-12 |
Not clear |
| Francis E Lotrich, Robert E Ferrell, Mordechai Rabinovitz, Bruce G Polloc. Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. Biological psychiatry. vol 65. issue 4. 2009-04-10. PMID:18801474. |
genetic differences in the serotonin reuptake transporter promoter (5-httlpr) may interact with the inflammatory system and influence depression risk. |
2009-04-10 |
2023-08-12 |
Not clear |
| S Dracheva, N Patel, D A Woo, S M Marcus, L J Siever, V Haroutunia. Increased serotonin 2C receptor mRNA editing: a possible risk factor for suicide. Molecular psychiatry. vol 13. issue 11. 2009-04-08. PMID:17848916. |
the serotonin 2c receptor (5-ht 2c r) has been implicated in depression and suicide. |
2009-04-08 |
2023-08-12 |
human |
| N H Kalin, S E Shelton, A S Fox, J Rogers, T R Oakes, R J Davidso. The serotonin transporter genotype is associated with intermediate brain phenotypes that depend on the context of eliciting stressor. Molecular psychiatry. vol 13. issue 11. 2009-04-08. PMID:18414408. |
a variant allele in the promoter region of the serotonin transporter gene, slc6a4, the s allele, is associated with increased vulnerability to develop anxiety-related traits and depression. |
2009-04-08 |
2023-08-12 |
human |
| Isabelle Boileau, Jerry J Warsh, Mark Guttman, Jean A Saint-Cyr, Tina McCluskey, Pablo Rusjan, Sylvain Houle, Alan A Wilson, Jeffrey H Meyer, Stephen J Kis. Elevated serotonin transporter binding in depressed patients with Parkinson's disease: a preliminary PET study with [11C]DASB. Movement disorders : official journal of the Movement Disorder Society. vol 23. issue 12. 2009-04-08. PMID:18661545. |
this study investigated whether abnormalities in serotonin transporter binding occur in parkinson's disease (pd) patients with concurrent depression. |
2009-04-08 |
2023-08-12 |
human |
| Isabelle Boileau, Jerry J Warsh, Mark Guttman, Jean A Saint-Cyr, Tina McCluskey, Pablo Rusjan, Sylvain Houle, Alan A Wilson, Jeffrey H Meyer, Stephen J Kis. Elevated serotonin transporter binding in depressed patients with Parkinson's disease: a preliminary PET study with [11C]DASB. Movement disorders : official journal of the Movement Disorder Society. vol 23. issue 12. 2009-04-08. PMID:18661545. |
compatible with recent pet/[(11)c]dasb findings in major depression, the present preliminary data suggest that increased [(11)c]dasb binding, possibly reflecting greater serotonin transporter density (up-regulation), might be a pathological feature of depression in parkinson's disease-and possibly a characteristic of depressive illness in general. |
2009-04-08 |
2023-08-12 |
human |
| Pan-Yue Deng, Saobo Le. Serotonin increases GABA release in rat entorhinal cortex by inhibiting interneuron TASK-3 K+ channels. Molecular and cellular neurosciences. vol 39. issue 2. 2009-04-08. PMID:18687403. |
application of 5-ht inhibited low-mg(2+)-induced seizure activity in slices via 5-ht(1a) and 5-ht(2a) receptors suggesting that 5-ht-mediated depression of neuronal excitability and increase in gaba release contribute to its anti-epileptic effects in the ec. |
2009-04-08 |
2023-08-12 |
rat |
| V L Misener, L Gomez, K G Wigg, P Luca, N King, E Kiss, G Daróczi, K Kapornai, Z Tamas, L Mayer, J Gádoros, I Baji, J L Kennedy, M Kovacs, A Vetró, C L Bar. Cytokine Genes TNF, IL1A, IL1B, IL6, IL1RN and IL10, and childhood-onset mood disorders. Neuropsychobiology. vol 58. issue 2. 2009-04-08. PMID:18832862. |
support for this is found in multiple lines of evidence, such as the effects of cytokines on the activities of the hypothalamic-pituitary-adrenal axis, serotonin and brain-derived neurotrophic factor, and hippocampal function, all of which are implicated in the etiology of depression. |
2009-04-08 |
2023-08-12 |
Not clear |
| Antonella Benvenuti, Paola Rucci, Mario Miniati, Alessandra Papasogli, Andrea Fagiolini, Giovanni B Cassano, Holly Swartz, Ellen Fran. Treatment-emergent mania/hypomania in unipolar patients. Bipolar disorders. vol 10. issue 6. 2009-04-08. PMID:18837867. |
the aim of this study was to estimate the incidence of treatment-emergent mania/hypomania (temh) and to describe the clinical characteristics of patients with major depression experiencing this event during treatment with a selective serotonin reuptake inhibitor (ssri) and/or interpersonal psychotherapy (ipt). |
2009-04-08 |
2023-08-12 |
Not clear |
| Chae-Moon Lim, Seung-Woo Kim, Ju-Young Park, Chaekyun Kim, Sung Hwa Yoon, Ja-Kyeong Le. Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. Journal of neuroscience research. vol 87. issue 4. 2009-04-08. PMID:18855941. |
fluoxetine is a selective serotonin reuptake inhibitor that is widely used in the treatment of major depression including after stroke. |
2009-04-08 |
2023-08-12 |
rat |
| T Frodl, N Koutsouleris, R Bottlender, C Born, M Jäger, M Mörgenthaler, J Scheuerecker, P Zill, T Baghai, C Schüle, R Rupprecht, B Bondy, M Reiser, H-J Möller, E M Meisenzah. Reduced gray matter brain volumes are associated with variants of the serotonin transporter gene in major depression. Molecular psychiatry. vol 13. issue 12. 2009-04-08. PMID:19008895. |
reduced gray matter brain volumes are associated with variants of the serotonin transporter gene in major depression. |
2009-04-08 |
2023-08-12 |
human |
| T Frodl, N Koutsouleris, R Bottlender, C Born, M Jäger, M Mörgenthaler, J Scheuerecker, P Zill, T Baghai, C Schüle, R Rupprecht, B Bondy, M Reiser, H-J Möller, E M Meisenzah. Reduced gray matter brain volumes are associated with variants of the serotonin transporter gene in major depression. Molecular psychiatry. vol 13. issue 12. 2009-04-08. PMID:19008895. |
the aim of the study was to examine in 77 patients with major depression and 77 healthy controls the association between the triallelic polymorphism in the promoter region of the serotonin transporter gene (5-httlpr) and gray matter (gm) brain volumes measured with 1.5 t magnetic resonance imaging. |
2009-04-08 |
2023-08-12 |
human |
| Ulf Guenther, Till Manzke, Hermann Wrigge, Matthias Dutschmann, Joerg Zinserling, Christian Putensen, Andreas Hoef. The counteraction of opioid-induced ventilatory depression by the serotonin 1A-agonist 8-OH-DPAT does not antagonize antinociception in rats in situ and in vivo. Anesthesia and analgesia. vol 108. issue 4. 2009-04-08. PMID:19299781. |
the counteraction of opioid-induced ventilatory depression by the serotonin 1a-agonist 8-oh-dpat does not antagonize antinociception in rats in situ and in vivo. |
2009-04-08 |
2023-08-12 |
rat |
| Bárbara Arias, Alessandro Serretti, Laura Mandelli, Cristóbal Gastó, Rosa Catalán, Diana De Ronchi, Lourdes Fañaná. Dysbindin gene (DTNBP1) in major depression: association with clinical response to selective serotonin reuptake inhibitors. Pharmacogenetics and genomics. vol 19. issue 2. 2009-04-07. PMID:19065121. |
dysbindin gene (dtnbp1) in major depression: association with clinical response to selective serotonin reuptake inhibitors. |
2009-04-07 |
2023-08-12 |
Not clear |
| Bárbara Arias, Alessandro Serretti, Laura Mandelli, Cristóbal Gastó, Rosa Catalán, Diana De Ronchi, Lourdes Fañaná. Dysbindin gene (DTNBP1) in major depression: association with clinical response to selective serotonin reuptake inhibitors. Pharmacogenetics and genomics. vol 19. issue 2. 2009-04-07. PMID:19065121. |
we investigated dysbindin gene (dtnbp1) variants in major depression and clinical response to selective serotonin reuptake inhibitors. |
2009-04-07 |
2023-08-12 |
Not clear |
| Ofer Agid, Bernard Lere. Algorithm-based treatment of major depression in an outpatient clinic: clinical correlates of response to a specific serotonin reuptake inhibitor and to triiodothyronine augmentation. The international journal of neuropsychopharmacology. vol 6. issue 1. 2009-04-06. PMID:12899735. |
algorithm-based treatment of major depression in an outpatient clinic: clinical correlates of response to a specific serotonin reuptake inhibitor and to triiodothyronine augmentation. |
2009-04-06 |
2023-08-12 |
Not clear |
| Stuart J Warden, Ian R Nelson, Robyn K Fuchs, Michael M Bliziotes, Charles H Turne. Serotonin (5-hydroxytryptamine) transporter inhibition causes bone loss in adult mice independently of estrogen deficiency. Menopause (New York, N.Y.). vol 15. issue 6. 2009-04-01. PMID:18725867. |
selective serotonin reuptake inhibitors (ssris) treat depression by antagonizing the serotonin (5-hydroxytryptamine) transporter (5-htt). |
2009-04-01 |
2023-08-12 |
mouse |
| Saloua Benmansour, Jonathan P Piotrowski, Alfonso V Altamirano, Alan Fraze. Impact of ovarian hormones on the modulation of the serotonin transporter by fluvoxamine. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 34. issue 3. 2009-03-30. PMID:18322468. |
blockade of serotonin transporter (sert) function by selective serotonin reuptake inhibitors (ssris) is the initial event that triggers a not completely understood process that results in clinical improvement in depression. |
2009-03-30 |
2023-08-12 |
rat |
| O Chernoloz, M El Mansari, P Blie. Sustained administration of pramipexole modifies the spontaneous firing of dopamine, norepinephrine, and serotonin neurons in the rat brain. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 34. issue 3. 2009-03-30. PMID:18688211. |
serotonin (5-ht), norepinephrine (ne) and dopamine (da) systems are known to be involved in the pathophysiology and treatment of depression. |
2009-03-30 |
2023-08-12 |
rat |